Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR Liposomes (fasudil + DETA NONOate)
- Development stage
- Preclinical
- Lead developer
- Vascular BioSciences
- Modality
- Small Molecules, Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Inhalation, Intratracheal
01
Overview
CAR Liposomes is an investigational inhalable combination therapy developed by Vascular BioSciences for the treatment of pulmonary arterial hypertension (PAH), with potential applications in sepsis and COVID-19. The drug utilizes a targeted liposomal delivery system where the liposomes are modified with the CAR peptide (CARSKNKDC), a cyclic homing peptide that selectively targets diseased pulmonary vascular endothelium. The liposomes encapsulate two active ingredients: fasudil, a Rho-kinase (ROCK) inhibitor, and DETA NONOate, a long-acting nitric oxide (NO) donor. This dual-action approach modulates both the RhoA/ROCK and NO pathways specifically within diseased lung tissue, aiming to induce selective pulmonary vasodilation, reduce mean pulmonary arterial pressure, and reverse vascular remodeling while minimizing systemic side effects like hypotension.
- Other names
- peptide-modified liposomeCAR-modified liposomes
02
Targets
ROCK1 (Rho-associated coiled-coil containing protein kinase 1)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)HS (Heparan sulfate)sGC (Soluble Guanylyl Cyclase)
Beyond the preview
Go deeper on CAR Liposomes (fasudil + DETA NONOate).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR Liposomes (fasudil + DETA NONOate).